How to buy Arcutis Biotherapeutics stock | $26.35

Arcutis Biotherapeutics, Inc is a biotechnology business based in the US. Arcutis Biotherapeutics shares (ARQT) are listed on the NASDAQ and all prices are listed in US Dollars. Arcutis Biotherapeutics employs 75 staff and has a market cap (total outstanding shares value) of 0.00.

Arcutis Biotherapeutics stock price (NASDAQ: ARQT)

Use our graph to track the performance of ARQT stocks over time.

Arcutis Biotherapeutics shares at a glance

• Key figures

Information last updated 2021-07-28.

Latest market close	$26.35
52-week range	$17.51 - $38.49
50-day moving average	$26.51
200-day moving average	$29.17
Wall St. target price	$55.13
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	$-1.15

Buy Arcutis Biotherapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Arcutis Biotherapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Arcutis Biotherapeutics, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Arcutis Biotherapeutics price performance over time

Historical closes compared with the close of $26.35 from 2021-05-28

1 week (2021-07-22)	N/A
1 month (2021-07-02)	26.35
3 months (2021-04-30)	-21.34%
6 months (2021-01-29)	N/A

1 year (2020-07-29)	N/A
2 years (2019-07-29)	N/A
3 years (2018-07-29)	N/A
5 years (2016-07-29)	N/A

Arcutis Biotherapeutics financials

Gross profit TTM	$0
Return on assets TTM	-25.26%
Return on equity TTM	-41.48%
Profit margin	0%
Book value	$9.04
Market capitalisation	$1.2 billion

TTM: trailing 12 months

Shorting Arcutis Biotherapeutics shares

There are currently 2.3 million Arcutis Biotherapeutics shares held short by investors – that's known as Arcutis Biotherapeutics's "short interest". This figure is 0.2% up from 2.3 million last month.

There are a few different ways that this level of interest in shorting Arcutis Biotherapeutics shares can be evaluated.

Arcutis Biotherapeutics's "short interest ratio" (SIR)

Arcutis Biotherapeutics's "short interest ratio" (SIR) is the quantity of Arcutis Biotherapeutics shares currently shorted divided by the average quantity of Arcutis Biotherapeutics shares traded daily (recently around 223130.83743842). Arcutis Biotherapeutics's SIR currently stands at 10.15. In other words for every 100,000 Arcutis Biotherapeutics shares traded daily on the market, roughly 10150 shares are currently held short.

However Arcutis Biotherapeutics's short interest can also be evaluated against the total number of Arcutis Biotherapeutics shares, or, against the total number of tradable Arcutis Biotherapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Arcutis Biotherapeutics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Arcutis Biotherapeutics shares in existence, roughly 50 shares are currently held short) or 0.077% of the tradable shares (for every 100,000 tradable Arcutis Biotherapeutics shares, roughly 77 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Arcutis Biotherapeutics.

Find out more about how you can short Arcutis Biotherapeutics stock.

Arcutis Biotherapeutics share dividends

We're not expecting Arcutis Biotherapeutics to pay a dividend over the next 12 months.

Arcutis Biotherapeutics overview

Arcutis Biotherapeutics, Inc. , a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical foam formulation of roflumilast for the treatment of seborrheic dermatitis and scalp psoriasis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; and ARQ-255, a topical formulation of ARQ-252 designed to reach deeper into the skin in order to treat alopecia areata. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019.

Frequently asked questions

What percentage of Arcutis Biotherapeutics is owned by insiders or institutions?
Currently 4.976% of Arcutis Biotherapeutics shares are held by insiders and 89.608% by institutions. How many people work for Arcutis Biotherapeutics?
Latest data suggests 75 work at Arcutis Biotherapeutics. When does the fiscal year end for Arcutis Biotherapeutics?
Arcutis Biotherapeutics's fiscal year ends in December. Where is Arcutis Biotherapeutics based?
Arcutis Biotherapeutics's address is: 3027 Townsgate Road, Westlake Village, CA, United States, 91361 What is Arcutis Biotherapeutics's ISIN number?
Arcutis Biotherapeutics's international securities identification number is: US03969K1088 What is Arcutis Biotherapeutics's CUSIP number?
Arcutis Biotherapeutics's Committee on Uniform Securities Identification Procedures number is: 03969K108